See the answer from John Reynders, VP, R&D strategy, program management, and data sciences at Alexion.
See the answer from Rachel King, the CEO of GlycoMimetics, a publicly traded biotech in Maryland.
See the answer from Mary Rose Keller, VP clinical operations at Heron Therapeutics. She has 30+ years of industry experience in clinical development strategy.
See the answer from Dr. Carol Nacy, CEO of Sequella, Inc., a private company that develops new anti-infective drugs.
See the answer from Ron Cohen, M.D., president, CEO, and founder of Acorda Therapeutics, a biotech developing therapies for spinal cord injury, MS, and other nervous system disorders.
See the answer from Jason Urban, Ph.D., who leads Bristol-Myers Squibb’s external engagement function within the Global Product Development & Supply (GPS) organization.
See the answer from Jeff Berkowitz, CEO and director of Real Endpoints, a data/analytics advisory firm.
See the answer from Sandra Poole, a senior biopharma executive with extensive technical operations, manufacturing, and business strategy experience.
See the answer from Jacks Lee, a global pharmaceutical executive with 25+ years of experiences in vaccines, biopharmaceuticals, and small molecule pharmaceuticals.
See the answer from Thomas Wiggans, chairman and CEO of Dermira, Inc.
Get the latest articles from Life Science Leader delivered to your inbox.